Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits. However, CVOT are scarcely representative of everyday clinical practice, and real-world studies could provide clinicians with more relatable evidence. Here, literature was thoroughly searched to retrieve real-world studies investigating the cardiovascular and renal outcomes of GLP-1RA vs. other glucose-lowering drugs and carry out relevant meta-analyses thereof. Most real-world studies were conducted in populations at low cardiovascular and renal risk. Of note, real-world studies investigating cardio-renal outcomes of GLP-1RA suggested that initiation of GLP-1RA was associated with a greater benefit on composite cardiovascular outcomes, MACE (major adverse cardiovascular events), all-cause mortality, myocardial infarction, stroke, cardiovascular death, peripheral artery disease, and heart failure compared to other glucose-lowering drugs with the exception of sodium-glucose transporter-2 inhibitors (SGLT-2i). Initiation of SGLT-2i and GLP-1RA yielded similar effects on composite cardiovascular outcomes, MACE, stroke, and myocardial infarction. Conversely, GLP-1RA were less effective on heart failure prevention compared to SGLT-2i. Finally, the few real-world studies addressing renal outcomes suggested a significant benefit of GLP-1RA on estimated glomerular filtration rate (eGFR) reduction and hard renal outcomes vs. active comparators except SGLT-2i. Further real-world evidence is needed to clarify the role of GLP-1RA in cardio-renal protection among available glucose-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 3×
“87) [16], yet these results were mainly driven by prevention of macroalbuminuria, whereas data on hard kidney endpoints were inconclusive due to the low number of events accrued [38].”
BackgroundResultCardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514 · cited 1×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundSGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999 · cited 1×
“Indeed, while SGLT-2i seemingly exert cardiovascular protection very early on after initial exposure [45], GLP-1RA likely require several months, especially in populations at low baseline cardiovascular risk [36]; thus, real-world studies might have been too short to detect the actual extent of GLP-1RA-mediated cardio…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · cited 1×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 367 · cited 1×
“Accordingly, data from Swedish and Danish nationwide registries demonstrated that GLP-1RA users exhibited a significantly reduced risk of lower limb amputations compared to SGLT-2i [37].”
BackgroundBray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153 · cited 1×
“suggested that poor adherence could account for up to 75% of the gap that can be found between randomized controlled trials and real-world studies results [52].”
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Overview of oxidative stress and inflammation in diabetes
Weinberg Sibony, R., Segev, O., Dor, S., & Raz, I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70014 · Cited by 292
Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100679 · Cited by 155
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 166
“Cardiovascular outcome trials (CVOT) showed that treatment with GLP-1RA is associated with significant cardiovascular benefits [60].”
BackgroundGourdy, P., Darmon, P., Dievart, F., Halimi, J.-M., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 127
Xie, Y., Bowe, B., Xian, H., Loux, T., McGill, J. B., & Al-Aly, Z. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00171-7 · Cited by 104
Socioeconomic aspects of incretin-based therapy
Karagiannis, T., Bekiari, E., & Tsapas, A. (2023) · Diabetologia · doi:10.1007/s00125-023-05962-z · Cited by 91
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Caruso, I., & Giorgino, F. (2024) · Endocrine · doi:10.1007/s12020-024-03757-9 · Cited by 60
“…glucose-lowering drugs after the fi rst year of treatment, demonstrating that new users of GLP-1RA with preserved kidney function at baseline had a slower eGFR decline and were less likely to have a ≥ 30% reduction in eGFR compared to initiators of other glucose-lowering drugs (Table 1) [31, 32].”
BackgroundSelf-citationTime-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Piccini, S., Favacchio, G., Panico, C., Morenghi, E., Folli, F., Mazziotti, G., Lania, A. G., & Mirani, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01800-z · Cited by 49
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 59
“Of note, however, no significant difference between GLP-1RAs and other glucose-lowering drug new users was noticed in any of the individual studies [18].”
InfluentialBaviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01572-y · Cited by 52
Self-citationGlucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
Evans, M., Kuodi, P., Akunna, C. J., McCreedy, N., Donsmark, M., Ren, H., & Nnaji, C. A. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231221740 · Cited by 33
“This fi nding is consistent with those of a previous meta-analysis of real-world studies, 10 while supporting the evidence of the cardiovascular ben-e fi ts of GLP-1 RA demonstrated by previous meta-analyses of placebo-controlled clinical trials.”
BackgroundResultInfluentialGlucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 31
Liarakos, A. L., Tentolouris, A., Kokkinos, A. D., Eleftheriadou, I., & Tentolouris, N. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108390 · Cited by 30
Diamond, C., Pansini, M., Hamid, A., Eichert, N., Pandya, P., Ali, S. N., Kemp, G. J., Thanabalasingham, G., Thomaides-Brears, H. B., & Cuthbertson, D. J. (2024) · Diabetes · doi:10.2337/db23-0926 · Cited by 27
Lui, D. T. W., Tang, E. H. M., Wu, T., Au, I. C. H., Lee, C., Woo, Y. C., Tan, K. C. B., & Wong, C. K. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01772-0 · Cited by 25
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 28
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133229 · Cited by 25
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01829-0 · Cited by 24
“Most data regarding the kidney effects of GLP-1 RAs come from cardiovascular outcome trials (CVOTs) enrolling patients with type 2 diabetes at high cardiovascular risk [12, 15] with a paucity of real-world data [18].”
BackgroundChuang, C., Wang, K., Chang, C., Lee, C., Huang, J., Wu, H., Yang, P., & Yang, S. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.90273 · Cited by 22
“The use of GLP-1RA has been shown to preserve the kidney function in T2DM patients [6, 7], and the use of GLP-1RA can also reduce the incidences of all-cause mortality, major adverse cardiovascular event and obesity [8, 9].”
BackgroundQuagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
“…and T2DM, GLP-1 Moreover, GLP1-RA is able to activate AMPK in endothelial and cardiac cells, improving mitochondrial metabolism and autophagy [26] (Figure 1); anti-inflammatory effects are mediated by the inhibition of the NLRP-3 and MyD-88 pathways, leading to increased adiponectin levels…”
Scheen, A. J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101474 · Cited by 22
Scheen, A. J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2354885 · Cited by 19
“In contrast, no significant differences were observed between GLP-1RAs and SGLT2is for all these items, except a lower reduction in HF with GLP-1RAs versus SGLT2is but a greater reduction in all-cause death with GLP-1RAs versus SGLT2is [54].”
BackgroundInfluentialInstituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
García‐Vega, D., Cinza‐Sanjurjo, S., Eirás, S., & González‐Juanatey, J. R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.04.032 · Cited by 17
Ohsugi, M., Eguchi, K., Mortensen, J. T., Yamamoto, Y., & Ueki, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110841 · Cited by 15
Terenzi, D. C., Bakbak, E., Teoh, H., Krishnaraj, A., Puar, P., Rotstein, O. D., Cosentino, F., Goldenberg, R., Verma, S., & Hess, D. C. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvae016 · Cited by 15
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Fan, Y.-C., Peng, S.-Y., Chang, C., Lee, C., Huang, J., Hsieh, M., & Yang, S. (2023) · Healthcare · doi:10.3390/healthcare11202749 · Cited by 15
“The treatment with GLP-1 agonists can preserve kidney function in general and T2DM patients [6,7].”
BackgroundPleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?
Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K., & Giugliano, D. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3627 · Cited by 13
“Of note, the majority of people with T2DM have no established CVD(4); therefore, the emerging real‐world evidence showing cardiovascular benefits of GLP‐1RAs in this population should be considered relevant, as they are associated with the reduction in composite cardiovascular outcomes, MACE, all‐ cause mortality, myo…”
BackgroundGlucagon-like peptide-1 receptor agonists in neoplastic diseases
Ji, L., He, X., Min, X., Yang, H., Wu, W., Xu, H., Chen, J., & Mei, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465881 · Cited by 12
Focus on Prevention: Peripheral Arterial Disease and the Central Role of the Cardiologist
Fioretti, V., Gerardi, D., Giugliano, G., Fazio, A. D., & Stabile, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134338 · Cited by 11
“There is now growing evidence to support the use of sodium–glucose cotransporter inhibitors (SGLT-2is) in patients with PAD and diabetes [48].”
ResultAla, M., & Aleaba, M. M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02459-3 · Cited by 12
Asif, M., Asif, A., Rahman, U. A., Farooqi, H. A., Fatima, O., Ali, W., Jafar, U., & Amin, M. H. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70059 · Cited by 13
Yeo, D., Jo, Y., Jeong, J., Jeong, Y. D., Woo, H. G., Son, Y., Kim, S., Rhee, S. Y., & Yon, D. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70298 · Cited by 15
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“The renal effects of GLP1-RAs have garnered significant attention in recent years, reflecting a broader understanding of their benefits beyond glycemic control in patients with T2DM [107, 108].”
BackgroundDutta, D., Mahajan, K., Kamrul-Hasan, A. B. M., Mahajan, N., Sharma, M., & Vohra, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70391 · Cited by 11
Mateos, I. C., Morales, C., & Aguilera, B. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155434 · Cited by 12
“…and delaying gastric emptying, which contributes to increased satiety and weight reduction [11,12]; given these pleiotropic effects, GLP-1 RAs have been positioned not only as antidiabetic agents but also as potential therapeutic tools in the management of obesity and cardiometabolic risk [13–15].”
Caballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
“In addition, these drugs delay gastric emptying, reduce appetite, and have been shown to improve cardiovascular risk factors [9–12].”
BackgroundSalmen, T., BOBIRCA, F. T., Bica, I.-C., Mihai, D. A., Pop, C. S., & Stoian, A. P. (2023) · Life · doi:10.3390/life13030839 · Cited by 11
“The data reported for GLP-1RAs in the treatment of T2DM show metabolic, weight, and CV benefits, alongside renal benefits such as a reduction in eGFR and complex renal outcomes [22,23].”
BackgroundConnolly, D. L., Collins, E., Ren, H., Ming, S. W. Y., Davidson, J. A., & Bain, S. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01715-w · Cited by 8
“Moreover, a 2022 meta-analysis of real-world studies demonstrated that GLP-1RAs reduced the risk of MACE by 30% compared with other glucose-lowering agents, including DPP4 inhibitors and insulin, across the included studies [18].”
Gudoor, R., Suits, A., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4030032 · Cited by 8
“…review of real-world studies determined that the initiation of SGLT-2is and GLP-1RAs yielded similar beneficial effects on composite CV outcomes, major adverse cardiac outcomes (MACEs), stroke, and MI, whereas SGLT-2is were more effective in the prevention of HF and all-cause mortality [65].”
BackgroundMonda, V. M., Voci, C., Strollo, F., Passaro, A., Greco, S., Monesi, M., Bigoni, R., Porcellati, F., Piani, D., Satta, E., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01472-8 · Cited by 7
“Therefore, it is conceivable that incretin-based therapies greatly help at the lung tissue level, thus extending their extra-glycemic effects well beyond those acknowledged in the cardiovascular and renal fields [36].”
BackgroundIrons, E. E., Pfeil, K. A., Perez, J. A., & van Besien, K. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103749 · Cited by 7
Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery
Brown, A., Patel, S. S., Kozato, A., Orandi, B. J., Massie, A. M., Vu, A. H., Somoza, E., Mei, T., Desai, S., Zhang, D. S., et al. (2026) · Obesity · doi:10.1002/oby.70246 · Cited by 8
Huang, X., Estau, D., Liu, X., Yu, Y., Tian, P., & Li, Z. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15405 · Cited by 7
Chepulis, L. M., Crosswell, R., Moorhouse, S., Morton, H., Oehley, M. R., Paul, R. G., & Crocket, H. R. (2024) · Journal of Primary Health Care · doi:10.1071/hc24056 · Cited by 6
King, A., Tan, X., Dhopeshwarkar, N., Bohn, R. L., Dea, K., Leonard, C. E., & de Havenon, A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100922 · Cited by 10
Morello, C. M., Awdishu, L., Lam, S., Heman, A., & Bounthavong, M. (2024) · Kidney360 · doi:10.34067/kid.0000000597 · Cited by 7
Dunn, T. J., Zhu, Y., Gronroos, N. N., Xie, L., Sargent, A., Gamble, C. L., & Billings, L. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112162 · Cited by 5
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 7
“Consistent with previous meta-analyses [3,4], the current study confirms that both SGLT2 inhibitors and GLP-1 receptor agonists reduce the incidence of MACE by 11-14% compared to placebo.”
Salmen, T., Rizvi, A. A., Rizzo, M., Pietroșel, V.-A., Bica, I.-C., Diaconu, C.-T., Potcovaru, C.-G., Salmen, B.-M., Coman, O. A., Bobirca, A. V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092455 · Cited by 5
“CVOTs that evaluated GLP-1 RAs with the standard–of-care treatment demonstrated that this class has beneficial effects on the reduction of HbA1c [17–19], fasting glycaemia [17–20], body weight [17–19], systolic and diastolic BP [17,19], and amelioration of the lipid profile [17,19] by reducing LDL-C, total-C, and TG l…”
BackgroundAktaş, G. (2025) · Advances in Clinical Pharmacology and Therapeutics · doi:10.63623/8cv4gh26 · Cited by 5
Zhang, J., Spall, H. G. C. V., Li, L., Khan, M. S., Pandey, A., Thabane, L., Bai, X., Wang, Y., Lip, G. Y. H., & Li, G. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102804 · Cited by 4
Charles, M., Schousboe, K., Thybo, T., Hall-Andersen, E. K., & Knudsen, S. T. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.05.002 · Cited by 3
Al-Kindi, S. G., Janus, S. E., Neeland, I. J., & Rajagopalan, S. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108224 · Cited by 3
Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents
Scheen, A. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00161-4 · Cited by 3
Shen, J., Sarwal, A., Singh, R., Hartsell, S. E., Wei, G., Nevers, M. R., Christensen, J. C., Takyi, A., Katkam, N., Derington, C. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16207 · Cited by 3
“16 A meta-analysis of ACNU studies of initiation of SGLT2i versus GLP-1RA 37 noted similar effects on major adverse cardiovascular events, stroke and myocardial infarction but GLP-1RA were less effective for heart failure prevention.”
Luo, Z., Chou, O. H. I., Ng, Z. M. W., Chung, C. T., Chan, J. S. K., Chan, R. N. C., Lü, L., Zhu, T., Cheung, B. M. Y., Liu, T., et al. (2023) · medRxiv · doi:10.1101/2023.11.06.23298185 · Cited by 3
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., Udell, J. A., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.010 · Cited by 2
Kwiendacz, H., Nabrdalik, K., Czupryniak, L., Klupa, T., Malecki, M. T., Myśliwiec, M., Strojek, K., & Gumprecht, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02567-1 · Cited by 2
Management of type 2 diabetes in patients with frailty
Hawker, K., Akter, R., Molnar, F., & Frank, C. (2024) · Canadian Family Physician · doi:10.46747/cfp.700130 · Cited by 3
“24”
Alshadfan, H., Mirghani, H. O., Alrasheed, T., Ibrahim, Y., Aljohani, S., Alanzi, T. S., Alshehri, S., Nurdin, A., & Abdullah, M. N. H. (2024) · Cureus · doi:10.7759/cureus.69805 · Cited by 2
“Furthermore, some long-acting drugs might not be licensed at the time of the original version [22].”
Backgroundde Carvalho, G. F., de Sousa, G. M. B., Moraes, G., Dorneles, H. B. F., Ferreira, L. C. L., Cury, G. A. A., Carvalho, M. D. O. P., & Lima, M. C. T. L. (2025) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.18n.1-235 · Cited by 1
Liu, Y., Barner, J. C., Lawson, K. A., Liu, Y., & Park, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378245 · Cited by 2
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100179 · Cited by 1
Renna, N. F., Zaidel, E. J., Corral, P., & Lerner, A. (2024) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2024.07.006 · Cited by 1
Danchin, N., Lemesle, G., Mazighi, M., Mohammedi, K., Schiele, F., Sibon, I., Caron, A., Emery, C., Nevoret, C., Vigié, L., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-087790 · Cited by 1
“…by an independent ethics committee (Comité éthique et scientifique pour les recherches, les études et les évaluations dans le domaine de la santé, Paris, France; reference: 8699786, dated 2 June 2022) and has been registered with the French National Data Protection Commission (Commission…”
Ураження нирок при артеріальній гіпертензії (діагностичні й терапевтичні аспекти)
Koval, S. M., Рєзнік, Л. А., Старченко, Т. Г., & Литвинова, О. М. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.369 · Cited by 1
Eisenberg, L. P., Huada, A. C. P., Gomes, M. E. C. C., GOUVEA, C. S. D. O., de Lima, L. P., Daura, R. J. A., Goulart, B. R. S., & Alves, H. F. D. A. (2025) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.18n.2-076 · Cited by 1
Prise en charge du diabète de type 2 chez les patients fragiles
Hawker, K., Akter, R., Molnar, F., & Frank, C. (2024) · Canadian Family Physician · doi:10.46747/cfp.7001e10
Miloslavsky, D. К., & Koval, S. M. (2024) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2024.01.120
Morales-González, G., González-Gálvez, G., García-García, J. E., Mancillas-Adame, L. G., del Castillo, M. A. M.-F., Almeda-Valdés, P., & Zúñiga-Guajardo, S. A. (2024) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m24000040
Effetti renali dei farmaci basati sul sistema delle incretine nelle persone con diabete di tipo 2
Caruso, I., Amato, C., Gravina, F., Montingelli, A., Giorgino, F., & Laviola, L. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01625-w
Self-citationShah, S. Z., Khan, R., Moeez, S., Kumar, S., Ejaz, M. U., Aslam, U., Mustafa, M. W., Ashraf, M. J., Mustafa, I., & Asim, F. (2025) · Cureus · doi:10.7759/cureus.92048
“This is consistent with prior real-world studies that matched GLP-1 RA and SGLT-2i cohorts to allow robust outcome comparisons [13,14].”
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26592413
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Figshare · doi:10.6084/m9.figshare.20580413
Self-citationLui, D. T. W., Tang, E. H. M., Wu, T., Au, I. C. H., Lee, C. H., Woo, Y. C., Tan, K. C. B., & Wong, C. K. H. (2024) · Figshare · doi:10.6084/m9.figshare.26571379
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Figshare · doi:10.6084/m9.figshare.20580410
Self-citationMazzeo, L., Sellasie, S. W., Pecchioli, C., Perna, P., Zaccaria, S., Sperti, P., Nardone, I., Giurato, L., Della-Morte, D., Caprio, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02756-5 · Cited by 1
Mohanty, S. S., Selvammathy, R. R., Ahad, H. A., & Kumar, E. S. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_1384_25 · Cited by 4
“[18] They usually have favorable safety profiles and are available in high amounts.”
Liu, R., Zhang, J., Chen, Z., Huang, W., Li, W., Shen, L., Cai, Y., Lei, Y., Zhou, M., Li, C., et al. (2026) · La radiologia medica · doi:10.1007/s11547-026-02237-6
Fang, Y.-Y., Bao, C.-Y., Liu, W., Xie, P.-F., Wang, C., Xiao-lin, Z., & Li, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1899085
“…effects independent of its hypoglycemic action, specifically including improved vascular endothelial function, inhibition of atherosclerotic plaque formation, modulation of the body’s inflammatory response, alleviation of oxidative stress damage, and improved myocardial energy metabolism (8, 9).”
Mavridis, A., Abzhandadze, T., Buvarp, D., Simons, K., Eliasson, B., von Euler, M., Viktorisson, A., & Sunnerhagen, K. S. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104220
Saleem, M. F., Mansoor, A., Shahid, E., Lohana, M., Ghafoor, M. S., Khan, M. U., Abbas, F. M., Hirpara, H., Khalid, A., Hassan, F., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3980
“Treatment adherence in real-world settings can differ from RCTs and may influence effectiveness outside trials [41].”
Piccini, S., Giuseppe, F., Panico, C., Emanuela, M., Franco, F., Mazziotti, G., Andrea, L., & Mirani, M. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7533471
Metadata
- Authors
- Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Giorgino, Francesco
- ORCID
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2022-02-15
- Volume
- 12
- Issue
- 2
- Pages
- 183
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC8879165
- OpenAlex
- W4213149093
- Semantic Scholar
- 30aa3d4bd64a5d1daebd8eb1180f4cb1fa26274b
- Cited by
- 86
- References
- 54
- Citations by year
- 2026: 8 · 2025: 20 · 2024: 25 · 2023: 27 · 2022: 6
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, cardiovascular outcomes, renal outcomes, sodium-glucose transporter 2 inhibitors, antidiabetic drugs, major adverse cardiovascular events, heart failure, estimated glomerular filtration rate, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.